Variant not associated with CLL, AIHA, or ITP in certain patients

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or autoimmune hematologic disorders in patients from the Republic of Macedonia. Past studies have shown an association between the PTPN22 R620W variant and both CLL and autoimmune diseases in patients from... [Read Article]
Print Friendly, PDF & Email

Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL

Print Friendly, PDF & Email


Ian W. Flinn, MD, PhD
Photo from Sarah Cannon
Final analysis of the phase 3 DUO trial has shown monotherapy with oral duvelisib results in a statistically significant improvement in progression-free survival (PFS) and overall response rate (ORR) compared to monotherapy with ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia/small lympchocytic lymphoma (CLL/SLL).... [Read Article]
Print Friendly, PDF & Email

FDA approves duvelisib for CLL/SLL and FL

Print Friendly, PDF & Email


Micrograph showing CLL
The U.S. Food and Drug Administration (FDA) has approved duvelisib (Copiktra™), a dual PI3K delta/gamma inhibitor, for two indications. Duvelisib has full FDA approval to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least two prior therapies. Duvelisib also has accelerated approval to... [Read Article]
Print Friendly, PDF & Email

CHMP supports new indication for venetoclax

Print Friendly, PDF & Email


U.S. version of venetoclax
Photo courtesy of Abbvie
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve a new indication for venetoclax (Venclyxto®). AbbVie is seeking EC approval for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic... [Read Article]
Print Friendly, PDF & Email

Stress linked to disease markers in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
New research has linked stress levels to markers of progressive disease in patients with chronic lymphocytic leukemia (CLL). Researchers found that CLL patients who reported more stress also had higher absolute lymphocyte counts and elevated levels of three other markers of more advanced disease—tumor necrosis factor-α (TNFα), interleukin 16 (IL-16), and chemokine... [Read Article]
Print Friendly, PDF & Email

MRD data added to venetoclax label

Print Friendly, PDF & Email


First month’s supply of
venetoclax (Venclexta)
Photo courtesy of Abbvie
The U.S. Food and Drug Administration (FDA) has expanded the label for venetoclax tablets (Venclexta®) to include data on minimal residual disease (MRD). The drug’s prescribing information now includes details on MRD negativity in previously treated patients with chronic lymphocytic leukemia (CLL) who received venetoclax... [Read Article]
Print Friendly, PDF & Email

Ibrutinib maintains efficacy over time

Print Friendly, PDF & Email


Micrograph showing CLL
Extended follow-up of the RESONATE-2 trial showed that first-line ibrutinib sustained efficacy in elderly patients with chronic lymphocytic leukemia (CLL). Patients who received ibrutinib had a long-term progression-free survival benefit over those who received chlorambucil. The depth of response to ibrutinib improved over time, which meant there was a substantial increase in... [Read Article]
Print Friendly, PDF & Email

Combo produces high response rate in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Bendamustine followed by obinutuzumab and venetoclax produces a high overall response rate in chronic lymphocytic leukemia (CLL), according to research published in The Lancet Oncology. In an ongoing, phase 2 study, researchers examined the outcomes of this treatment in 66 patients with CLL. Patients underwent initial debulking with two cycles of bendamustine,... [Read Article]
Print Friendly, PDF & Email

Real-world bleeding risk with ibrutinib

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and anticoagulation therapy in a clinical setting. Caution should be used when weighing the risks and benefits of ibrutinib for patients already taking antiplatelet or... [Read Article]
Print Friendly, PDF & Email

Group releases new CLL guidelines

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do not have TP53 disruption, according to new guidelines from the British Society for Haematology. The guidelines update the 2012 recommendations on CLL to include “significant” developments in treatment. The... [Read Article]
Print Friendly, PDF & Email

Team recommends melanoma screening in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Patients with chronic lymphocytic leukemia (CLL) should be routinely monitored for melanoma, according to researchers. A study of 470 CLL patients showed they have a significantly higher risk of invasive melanoma than the general population. Most of the melanomas reported in this study were detected via routine surveillance, and most were discovered... [Read Article]
Print Friendly, PDF & Email

Transplant strategy not viable for aggressive B-NHL

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-Hodgkin lymphomas (NHLs), according to researchers. Long-term follow-up data showed “excellent” outcomes in patients with indolent B-NHL who received conditioning with 90Y-ibritumomab tiuxetan plus fludarabine and low-dose total body irradiation (TBI) prior... [Read Article]
Print Friendly, PDF & Email

Group updates guidelines on CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Recent advances in chronic lymphocytic leukemia (CLL) have prompted an update to the 2008 International Workshop in Chronic Lymphocytic Leukemia (iwCLL) consensus guidelines. The updated iwCLL guidelines include new information on genomic alterations, the use of clinical staging and prognostic markers/scores, response assessment, minimal residual disease (MRD), and viral diseases in... [Read Article]
Print Friendly, PDF & Email

Combo proves ‘beneficial’ for ‘unfit’ CLL patients

Print Friendly, PDF & Email


Valentin Goede, MD
Obinutuzumab plus chlorambucil (G-Clb) is a “valid and beneficial” frontline treatment option for “unfit” patients with chronic lymphocytic leukemia (CLL), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Final results from the CLL11 study have revealed additional benefits of G-Clb over rituximab plus chlorambucil (R-Clb) in... [Read Article]
Print Friendly, PDF & Email